Article info
PDFRespiratory infection
Original research
SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis
- Correspondence to Dr Christian Fynbo Christiansen, Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, Denmark; cfc{at}clin.au.dk
Citation
SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis
Publication history
- Received July 12, 2020
- Revised October 14, 2020
- Accepted November 3, 2020
- First published December 8, 2020.
Online issue publication
September 01, 2022
Article Versions
- Previous version (15 March 2021).
- Previous version (15 March 2021).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage